An observational study in Hypotension and Cesarean Section Complications, sponsored by Johann Wolfgang Goethe University Hospital. Completed at 1 site in Germany. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-16.
Sponsored by Johann Wolfgang Goethe University Hospital · Observational
The aim of the present study is to quantify the dose and usage of sympathomimetics used in caesarean section.
Recent metaanalysis showed significantly reduced hypotension and bradycardia in patients undergoing caesarean section in spinal anesthesia when 5-hydroxytryptamine 3 receptor antagonists were used prophylactically.
Due to this fact in our clinic the standard procedure was changed. All patients for caesarean section receive Granisetron before spinal anesthesia.
The aim of the present study is to evaluate the usage and dose of sympathomimetics during spinal anesthesia.
Therefore the investigators will evaluate approximately 120 participants who received granisetron and 120 participants who did not receive 5-hydroxytryptamine 3 receptor antagonists.
All patients who underwent spinal anesthesia for caesarean section in out clinic.
Exclusion Criteria:
120 Patients prior to changes of intern standards of caesarean section. Before march 2017 no patient undergoing elective caesarean section received Granisetron as a matter of routine.
Drug: No Granisetron
120 Patients after changes of intern standards of caesarean section. After march 2017 all patient undergoing elective caesarean section received Granisetron as a matter of routine.
Drug: Granisetron Hydrochloride
Patients received Granisetron.
Also known as: Granisetron, 5-hydroxytryptamine 3 receptor antagonist
Patients who did not receive Granisetron.
Sympathomimetics
Type of sympathomimetics during during the operation
Time frame: 30 minutes starting with induction of spinal anesthesia.
Sympathomimetics
Cumulative dose of sympathomimetics during during the operation
Time frame: 30 minutes starting with induction of spinal anesthesia.
Volume substitution
Type of perioperative infused volume during the operation
Time frame: 30 minutes starting with induction of spinal anesthesia.
Volume substitution
Cumulative volume of perioperative infused volume during the operation
Time frame: 30 minutes starting with induction of spinal anesthesia.
Haemotherapy
Type of haemotherapy.
Time frame: 30 minutes starting with induction of spinal anesthesia.
Haemotherapy
Cumulative volume of haemotherapy.
Time frame: 30 minutes starting with induction of spinal anesthesia.
Duration until first application of sympathomimetics
Duration until first administration of any kind of sympathomimetics.
Time frame: 30 minutes starting with induction of spinal anesthesia.
Oxytocin
Duration until first administration of oxytocin.
Time frame: 30 minutes starting with induction of spinal anesthesia.
Oxytocin
Cumulative dose of Oxytocin.
Time frame: 30 minutes starting with induction of spinal anesthesia.
Uterotonic agents
Kind of uterotonic agents.
Time frame: 30 minutes starting with induction of spinal anesthesia.
Uterotonic agents
Cumulative dose of uterotonic agents.
Time frame: 30 minutes starting with induction of spinal anesthesia.
Plan to share: No
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johann Wolfgang Goethe University Hospital